Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
Julian Friebel(Feuerwehr Dortmund), Ursula Rauch(Charité - Universitätsmedizin Berlin), Rainer Glauben(German Cancer Research Center), Arash Haghikia(German Centre for Cardiovascular Research), Elisabeth Strässler(German Centre for Cardiovascular Research), Stella Lammel(Charité - Universitätsmedizin Berlin), Eileen Moritz(Universitätsmedizin Greifswald), Verena Moos(Humboldt-Universität zu Berlin), Marianna Puccini(Charité - Universitätsmedizin Berlin), Stephan B. Felix(Universitätsmedizin Greifswald), Kai Jakobs(Charité - Universitätsmedizin Berlin), Daniel Steffens(The University of Sydney), Heinz-Peter Schutheiss(CS Diagnostics), Ulf Landmesser(Deutsches Herzzentrum der Charité), Bernhard H. Rauch(Carl von Ossietzky Universität Oldenburg), Franziska Nowak(Charité - Universitätsmedizin Berlin), Marco Witkowski(Cleveland Clinic), Nicolle Kränkel(Leipzig Heart Institute), Andrea Dörner(Charité - Universitätsmedizin Berlin)
Cited by 29
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 ESC Guidelines for the management of endocarditis
|European Heart Journal|2023|1.6k